|
Adult Congenital Heart Disease Services (Levels 1 and 2) for people aged 16 and over, Service Specification (CP214). June 2022 (PDF, 423Kb)
|
|
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (all ages), (PP162) March 2025 (PDF, 236Kb)
|
|
Complex Devices Implantable Cardioverter Defibrillators and Cardiac Resynchronisation Therapy for arrhythmias and heart failure (PP151) March 2025 (PDF, 234Kb)
|
|
Electrophysiology and Ablation Services (16 years and older), Commissioning policy (CP197a) January 2025 (PDF, 347Kb)
|
|
Electrophysiology and Ablation Services (16 years and older), Service Specification (CP197b) January 2025 (PDF, 331Kb)
|
|
Everolimus for the prevention of organ rejection following heart transplantation, Policy Position (PP103), July 2019 (PDF, 164Kb)
|
|
Extra corporeal membrane oxygenation (ECMO) service for adults with cardiac failure, Policy Position Statement, (PP102). July 2019 (PDF, 141Kb)
|
|
Percutaneous Mitral Valve Leaflet repair for primary degenerative mitral regurgitation in adults, Policy Position Statement (PPS206), June 2021 (PDF, 572Kb)
|
|
Personalised External Aortic Root Support (PEARS) for surgical management of enlarged aortic root (adults), Policy Position Statement, (PP104). March 2025 (PDF, 195Kb)
|
|
Selexipag for the Treatment of Pulmonary Arterial Hypertension (Adults), Policy Position (PP105), March 2019.pdf (PDF, 255Kb)
|
|
Trans-catheter Aortic Valve Implantation (TAVI) for Severe Symptomatic Aortic Stenosis (SSAS), Commissioning Policy (CP58), March 2019 (PDF, 295Kb)
|